The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Clinical Practice Experience With NovoTTF-100A™ System for Glioblastoma: The Patient Registry Dataset (PRiDe)
Open accessAbstract
Recurrent glioblastoma multiforme (GBM) is a highly aggressive cancer with poor prognosis, and an overall survival of 6 to 7 months with optimal therapies. The NovoTTF-100A™ System is a novel antimitotic cancer therapy recently approved for the treatment of recurrent GBM, based on phase III (EF-11) trial results. The Patient Registry Dataset (PRiDe) is a post-marketing registry of all recurrent GBM patients who received NovoTTF Therapy in a real-world, clinical practice setting in the United States between 2011 and 2013. Data were collected from all adult patients with recurrent GBM who began commercial NovoTTF Therapy in the United States between October 2011 and November 2013. All patients provided written consent before treatment was started. Overall survival (OS) curves were constructed for PRiDe using the Kaplan-Meier method. Median OS in PRiDe was compared for patients stratified by average daily compliance (≥75% v<75% per day) and other prognostic variables. Adverse events were also evaluated. Data from 457 recurrent GBM patients who received NovoTTF Therapy in 91 US cancer centers were analyzed. More patients in PRiDe than the EF-11 trial received NovoTTF Therapy for first recurrence (33% v 9%) and had received prior bevacizumab therapy (55.1% v 19%). Median OS was significantly longer with NovoTTF Therapy in clinical practice (PRiDe data set) than in the EF-11 trial (9.6 v 6.6 months; HR, 0.66; 95% CI, 0.05 to 0.86, P = .0003). One- and 2-year OS rates were more than double for NovoTTF Therapy patients in PRiDe than in the EF-11 trial (1-year: 44% v 20%; 2-year: 30% v 9%). First and second versus third and subsequent recurrences, high Karnofsky performance status (KPS), and no prior bevacizumab use were favorable prognostic factors. No unexpected adverse events were detected in PRiDe. As in the EF-11 trial, the most frequent adverse events were mild to moderate skin reactions associated with application of the NovoTTF Therapy transducer arrays. Results from PRiDe, together with those previously reported in the EF-11 trial, indicate that NovoTTF Therapy offers clinical benefit to patients with recurrent GBM. NovoTTF Therapy has high patient tolerability and favorable safety profile in the real-world, clinical practice setting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This conclusion is supported by clinical observations where overall survival outcomes are more favorable in those patients with recurrent glioblastoma who maintain higher therapeutic compliance with TTFields therapy10.”
From Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells (2015) · cites this paper as [10]
Citations
Cites
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., TAPHOORN, M. J. B., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Bélanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,980
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N. A., Nicholas, M. K., Jensen, R. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,516
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
The epidemiology of glioma in adults: a "state of the science" review
Ostrom, Q. T., Bauchet, L., Davis, F. G., Deltour, I., Fisher, J. L., Langer, C. E., Pekmezci, M., Schwartzbaum, J., Turner, M. C., Walsh, K. M., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou087 · Cited by 2,320
Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M. A., Butman, J. A., Camphausen, K. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,567
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J. E., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J. H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,417
Riegel, B. J., Moser, D. K., Anker, S. D., Appel, L. J., Dunbar, S. B., Grady, K. L., Gurvitz, M. Z., Havranek, E. P., Lee, C. S., Lindenfeld, J. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192628 · Cited by 984
Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials
Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., Levin, V. A., & Yung, W. K. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2572 · Cited by 902
Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors
Kirson, E. D., Dbalý, V., Tovaryš, F., Vymazal, J., Soustiel, J. F., Itzhaki, A., Mordechovich, D., Steinberg-Shapira, S., Gurvich, Z., Schneiderman, R., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702916104 · Cited by 894
Stupp, R., Wong, E. T., Kanner, A. A., Steinberg, D., Engelhard, H., Heidecke, V., Kirson, E. D., Taillibert, S., Liebermann, F., Dbalý, V., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.011 · Cited by 862
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Kirson, 2010, Modeling tumor growth kinetics and its implications for TTFields treatment planning. [abstract], Neurooncology (Meeting Abstracts), 12
Cited by
Sorted by citations
Items 101–152 of 152
RNAi therapeutics for brain cancer: current advancements in RNAi delivery strategies
Malhotra, M., Toulouse, A., Godinho, B. M. D. C., Carthy, D. J. M., Cryan, J. F., & O’Driscoll, C. M. (2015) · Molecular BioSystems · doi:10.1039/c5mb00278h · Cited by 8
Efficacy and Safety of Treating Glioblastoma With Tumor-Treating Fields Therapy
Saria, M. G., & Kesari, S. (2016) · Clinical journal of oncology nursing · doi:10.1188/16.cjon.s1.9-13 · Cited by 8
Gencturk, E., Ülgen, K. Ö., & Mutlu, S. (2020) · Biomicrofluidics · doi:10.1063/5.0008462 · Cited by 8
Eckert, T., Suresh, R. E., Zobaer, M. S., & Rowland, N. C. (2025) · Brain stimulation · doi:10.1016/j.brs.2025.07.018 · Cited by 7
Jin, J., Xue, H., Chen, K., Su, Y., Hu, X., Hu, X., Huang, X., Jiang, L., Wu, J., & Peng, X. (2025) · Advanced Science · doi:10.1002/advs.202511604 · Cited by 7
Tumor-Treating Fields and Related Treatments in the Management of Pediatric Brain Tumors
Rousseau, J., Lapointe, S., & Roberge, D. (2025) · Current Oncology · doi:10.3390/curroncol32040185 · Cited by 6
Effects of 2.4 GHz radiofrequency electromagnetic field (RF-EMF) on glioblastoma cells (U -118 MG)
Nowak, A., Górski, R., Marszałek, M., Wosiński, S., Przesmycki, R., Bugaj, M., Nowosielski, L., Baranowski, M., & Zeyland, J. (2023) · Annals of Agricultural and Environmental Medicine · doi:10.26444/aaem/176405 · Cited by 5
Stereotactic radiosurgery for recurrent high-grade gliomas: a systematic review
Kite, T. S., Bossinger, B., Yadlapalli, V., Jaffee, S., Herbst, J., Karlovits, S., Wegner, R. E., & Shepard, M. J. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-025-05156-0 · Cited by 5
Encarnación-Santos, D. A., Chmutin, G. E., Bozkurt, İ., Welligton, J., & Chaurasia, B. K. (2024) · Annals of Oncology Research and Therapy · doi:10.4103/aort.aort_5_24 · Cited by 5
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Riley, M. M., San, P., Lok, E., Swanson, K. D., & Wong, E. T. (2019) · Journal of Visualized Experiments · doi:10.3791/58937-v · Cited by 5
Velasco, M. T., Álvarez-Gallego, R., Peinado, P., Muñoz, C. G., Ugidos, L., García-Morillo, M., Vicente, E., Quijano, Y., Prados, S., de la Fuente, E., et al. (2024) · Case Reports in Oncology · doi:10.1159/000539719 · Cited by 4
Li, X., Oziel, M., & Rubinsky, B. (2022) · PeerJ · doi:10.7717/peerj.12877 · Cited by 4
Current status and research progress of minimally invasive treatment of glioma
Wu, H., Zhou, F., Gao, W., Chen, P., Yao, W., Wang, F., & Zhao, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1383958 · Cited by 4
Lok, E., San, P., & Wong, E. T. (2019) · Springer eBooks · doi:10.1007/978-3-030-21293-3_8 · Cited by 4
Supportive Care in Patients Using Tumor Treating Fields Therapy
Lacouture, M. E., DeNigris, J., & Kanner, A. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-30576-9_9 · Cited by 4
Tumor treating fields for newly diagnosed glioblastoma: a retrospective analysis
Wang, C., Xu, H., Hu, Y., Ma, L., Ren, Q., & Yu, S. (2026) · Journal of Neuro-Oncology · doi:10.1007/s11060-026-05467-w · Cited by 3
Tumor treating fields: a new treatment for glioblastoma
Slavkov, D., Hadzhiyanev, A., & Troyanova-Slavkova, S. (2023) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2022.2155567 · Cited by 3
Lantos, J. E., Young, R. J., Miranda, P. C., Wenger, C., & Wong, E. T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800945-1.00025-2 · Cited by 3
Progress on TTFields combined with other therapies for glioblastoma treatment: A narrative review
Cao, Y. B., Wu, H., Tang, B., Li, M., Wan, Y., Duan, J., & Xu, J. (2022) · Glioma · doi:10.4103/glioma.glioma_12_22 · Cited by 2
Biedermann, G. B., Merrifield, K., & Lustgarten, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1441146 · Cited by 2
Smothers, A. R. (2025) · American Journal of Cancer Research · doi:10.62347/lxjh5896 · Cited by 2
Kütük, T., Walker, J. M., Ballo, M. T., Cameron, R. B., Alvarez, J. B., Chawla, S., Luk, E., Behl, D., Pra, A. D., Morganstein, N., et al. (2023) · Current Oncology · doi:10.3390/curroncol30060394 · Cited by 2
Therapeutic approaches to overcome temozolomide resistance in glioblastoma
Gergues, M., Savanur, V. H., Prado, D., Eljarrah, A., Liu, J. K., Jaloudi, M., & Rameshwar, P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821567-8.00012-9 · Cited by 2
Glioblastoma: A molecular insight into current discoveries and treatment directions
Świątek, W., Kłodziński, O., Ciesielski, M., Adamkiewicz, Z. A., Podolak, M., Mozdziak, P. E., & Kranc, W. (2024) · Medical Journal of Cell Biology · doi:10.2478/acb-2024-0001 · Cited by 2
Enhancing the therapeutic efficacy of tumor-treating fields (TTFields): further perspectives
Kumaria, A. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03942-w · Cited by 1
A Pulsed Tumor Treating Fields Protocol to Improve Glioblastoma Therapy
Lv, Y., Lu, S., Wang, H., Zhang, J., & Chen, C. (2025) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2025.3634604 · Cited by 1
Li, G., Qiu, X., Zhang, W., Hu, M., Qin, Z., Wang, Y., Wu, J., Guo, W., He, X., You, Y., et al. (2026) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdag110 · Cited by 1
Tumor-Treating Electric Fields for Glioblastoma
Swanson, K. D., Lok, E., & Wong, E. T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-47660-7.00017-3 · Cited by 1
Novel Focal Treatment Modalities in Glioma Management
Chakraborty, S., Wagner, K. E., Boockvar, J. A., & Schulder, M. (2018) · Springer eBooks · doi:10.1007/978-3-319-95918-4_25 · Cited by 1
Goldman, S., Margol, A., Hwang, E. I., Tanaka, K., Suchorska, B., Crawford, J. R., & Kesari, S. (2022) · Vide Leaf, Hyderabad eBooks · doi:10.37247/pacr2ed.2.22.30 · Cited by 1
de Godoy, L. L., Rajan, A., Banihashemi, A., Patel, T., Desai, A. S., Bagley, S. J., Brem, S. S., Chawla, S., & Mohan, S. (2025) · Brain Sciences · doi:10.3390/brainsci15020146 · Cited by 1
Mahdy, S., Mohammed, H. S., & Hamdy, O. (2025) · Computer Methods in Biomechanics & Biomedical Engineering · doi:10.1080/10255842.2025.2542939 · Cited by 1
Tumor Treating Fields in Clinical Practice with Emphasis on PRiDe Registry
Ruzevick, J., Wong, E. T., & Mrugała, M. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-30576-9_7 · Cited by 1
Sumrall, A. L. (2017) · doi:10.1002/9781119196235.ch63
NovoTTF-100A System as a treatment for Glioblastoma
Morrison, A. (2018) · CommonKnowledge Research Repository (Pacific University Oregon)
Adjuvant therapy and molecular profiling for inoperable gliomas
Wedemeyer, M. A., & Zada, G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813633-1.00014-1
Skull Modulated Strategy to Intensify Tumor Treating Fields on Brain Tumor: a Finite Element StudyPreprint
Yang, X. S., Liu, P., Xing, H., Wen, X., Wang, Y., Hu, C., Li, L., & Ma, W. (2021) · Research Square · doi:10.21203/rs.3.rs-470112/v1
Lieberman, F. S. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.726771952.793537829
Díaz, M., Young, R. J., Miranda, P. C., Wenger, C., Lantos, J. E., & Wong, E. T. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822835-7.00002-0 · Cited by 1
Abutbul, A., Mumblat, Y., Porat, Y., Friedman, N., Atari, N., Sharabi, S., Nama, A., Mugahed, W., Kessler, A., Kolben, Y., et al. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1296558
Liang, L., Chen, L., Ni, C., Shi, W., Zhou, Z., Chen, S., Zhu, W., Liu, J., Qiu, X., Lin, W., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4350426/v1
Advances in tumor treating fields for solid tumors: Mechanism, evidence and future outlook
Chen, Y., Wu, H., Yang, L., Fang, C., & Zhang, H. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105194
Update on glioblastoma: Biology, clinical management and emerging therapeutic strategies (Review)
Ahmed, S., & Abdalla, B. A. (2026) · World Academy of Sciences Journal · doi:10.3892/wasj.2026.439
Wang, Z., Jiang, Z., Zong, D., Zhu, H., Zou, G., Xu, J., Guo, W., Ge, Y., Wang, X., Yu, J., et al. (2026) · Medicine · doi:10.1097/md.0000000000048383
Corrales-García, E. M., López, P. D. D., Sepúlveda-Sánchez, J. M., Leal, R. G., Lendínez-Sánchez, G., Cabezas-Camarero, S., Isac, M. S., Miguel, H. H., Moreno, A. M. R., Santos, J. A. C., et al. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04401-w
Neuromodulation in Neuro-Oncology: A Scoping Review
Kamaludin, A. I., Kumaria, A., & Ashkan, K. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16070349
Kebir, S., Oster, C., Sharma, S., Jekel, L., Schmidt, T., Grieger, J., Cappello, G., Kizina, K., Lazaridis, L., Rauschenbach, L., et al. (2026) · BMC Cancer · doi:10.1186/s12885-026-16613-y
Metadata
- Authors
- Mrugala, M. M., Engelhard, H. H., Dinh Tran, D., Kew, Y., Cavaliere, R., Villano, J. L., Annenelie Bota, D., Rudnick, J., Love Sumrall, A., Zhu, J.-J., & Butowski, N.
- Affiliations
- University of Illinois Hospital & Health Sciences System (US)
- Houston Methodist (US)
- The Ohio State University (US)
- University of Illinois Chicago (US)
- Cedars-Sinai Medical Center (US)
- The University of Texas Health Science Center at Houston (US)
- University of California, San Francisco (US)
- ORCID
- Venue
- Seminars in Oncology
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 41
- Pages
- S4-S13
- ISSN
- 0093-7754 (ISSN-L)
- OpenAlex
- W1994913111
- Cited by
- 152
- References
- 36
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 12 · 2023: 14 · 2022: 25 · 2021: 12 · 2020: 11 · 2019: 8 · 2018: 13 · 2017: 12 · 2016: 13 · 2015: 13
- FWCI
- 6.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Seminars in Oncology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- overall survival, medication adherence, bevacizumab, prognostic factors, Karnofsky performance status, adverse events, skin reactions, real-world clinical practice, first recurrence
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Combined Modality Therapy, Electric Stimulation Therapy, Female, Follow-Up Studies, Glioblastoma, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Practice Patterns, Physicians', Prognosis, Registries, Survival Rate, Clinical Trials, Phase III as Topic, Young Adult, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
